Jim Dynes, a stage 4 pancreatic cancer patient in Cincinnati, is reporting improved quality of life after participating in a clinical trial at the University of Cincinnati Cancer Center.
- Daraxonrasib acts as a KRAS inhibitor, a type of medication that targets a specific protein mutation responsible for signaling cancer cells to grow uncontrollably.
- The treatment is administered as a daily oral pill, often in combination with periodic chemotherapy infusions, to maintain disease stability.
- Patients like Dynes are shifting from a terminal prognosis to a model of chronic disease management, allowing for better daily functional status.
The therapeutic efficacy of daraxonrasib lies in its mechanism of action as a KRAS inhibitor. In many pancreatic cancer cases, the KRAS gene acts as a molecular “on-switch” that remains permanently active, driving rapid tumor proliferation. By binding to this protein, the drug effectively turns the switch off, hindering the signaling pathways that sustain tumor growth.
“I can go back home, and I can go out and play golf. I can go play music. I'm in a band and I haven't missed a day yet,” Jim Dynes said.
Dr. Davendra Sohal, MD, of the University of Cincinnati Cancer Center, described the significance of this transition in treatment protocols. “It is a pill. It is called a caries inhibitor KRAS and the KRAS is like an on switch in cancer. It’s a switch that turns on and the cancer is on and keeps growing, and this drug essentially turns that switch off and turns the cancer off,” Sohal said.
The availability of this therapy at the University of Cincinnati Cancer Center follows the drug’s FDA approval in August. Daraxonrasib received official FDA approval in August and is now available at the University of Cincinnati Cancer Center. The process of bringing such trials to local patients is intensive, often requiring up to a year of logistical preparation and regulatory oversight to ensure safety and clinical protocol adherence.
“Pancreas cancer used to be a death sentence. It used to be a terminal illness for many patients, unfortunately, but now I think we have turned that terminal illness into a chronic illness,” Sohal said.
| Treatment Component | Administration Method | Target/Function |
|---|---|---|
| Daraxonrasib | Daily oral pill | KRAS protein inhibition |
| Chemotherapy | Monthly infusion | Cytotoxic cell suppression |
| Surgery | Procedure (Initial) | Tumor debulking/Assessment |
For Jim Dynes, the clinical trial has provided a window of time to engage in personal milestones, including his sons’ weddings and upcoming holiday gatherings. He now describes his stage 4 diagnosis as a “bump in the road,” emphasizing the psychological impact of having viable treatment options.
Following his participation as one of the first patients on the trial, Dynes continues his daily regimen.
“I didn’t think I was going to make it until Christmas. Well, I’ve made it to two of them. I’m getting ready to approach another one and Thanksgiving is just around the corner and they’re all going to be there and then the house is going to be loud and noisy and stuff everywhere. But that’s what life is, right?” Dynes said.
